Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Becaplermin + bovine collagen matrix** is a combination product consisting of recombinant human platelet-derived growth factor BB (becaplermin/rhPDGF-BB) and a matrix made of type I collagen derived from bovine sources. The recombinant growth factor promotes wound and tissue healing by stimulating angiogenesis, recruiting and inducing proliferation of fibroblasts and cells involved in tissue repair, promoting extracellular matrix formation, and enhancing granulation tissue. The **bovine collagen matrix** serves as a delivery scaffold that supports cellular ingrowth and provides structural support while modulating proteases in the wound, protecting growth factors from degradation, releasing them gradually, and accelerating tissue regeneration. This combination is used for applications including chronic wound healing and bone grafting (as in AUGMENT Injectable), especially for diabetic foot ulcers and orthopedic indications such as bone defects or non-unions[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on becaplermin + bovine collagen matrix.